RecruitingNot ApplicableNCT06445361
Prevalence of NAFLD in T1DM Patients
The Prevalence of Non-Alcoholic Fatty Liver Disease in Type 1 Diabetes Mellitus Patients Followed at Ziekenhuis Oost-Limburg, Genk, Belgium
Sponsor
Ziekenhuis Oost-Limburg
Enrollment
138 participants
Start Date
Jul 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
To determine the prevalence of NAFLD in T1DM patients.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study measures how common non-alcoholic fatty liver disease (NAFLD) — a condition where fat builds up in the liver — is among people with type 1 diabetes. Having diabetes increases liver disease risk, but how prevalent it is specifically in type 1 diabetes is not well understood.
**You may be eligible if...**
- You have type 1 diabetes
- You are 18 years of age or older
- You are able to give written informed consent
**You may NOT be eligible if...**
- You drink excessive amounts of alcohol
- You have another identified cause of liver disease or liver fat buildup
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIAGNOSTIC_TESTFibroScan
Performance of a FibroScan measurement to determine steatosis and fibrosis.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06445361
Related Trials
Impact of MEnstruation on Glycemic Response and Exercise In Females With Type 1 Diabetes
NCT062979801 location
DASH-Obesity: Explainable AI for Family-Centric Personalized Weight Control in Adolescents and Young Adults With Obesity and Chronic Conditions
NCT076383451 location
Simultaneous Measurement and Responsive Treatment - Part 2
NCT076550761 location
Accuracy of Continuous Glucose Monitors During the Perioperative Period in Youth With Type 1 Diabetes
NCT065758421 location
Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant
NCT054240031 location